Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin Pharmaceuticals has received the US Food and Drug Administration (FDA) approval to market its levetiracetam 500mg and 750mg extended-release tablets.
Subscribe to our email newsletter
Lupin’s levetiracetam 500mg and 750mg extended-release tablets are generic equivalent to Keppra XR tablets of UCB.
Keppra is indicated for the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.
Lupin has already started shipping the drug.